Cargando…
Comparison of Tau and Amyloid-β Targeted Immunotherapy Nanoparticles for Alzheimer’s Disease
Alzheimer’s disease (AD) is a rapidly growing global concern associated with the accumulation of amyloid-β plaques and intracellular neurofibrillary tangles in the brain combined with a high acetylcholinesterase activity. AD diagnosis is usually made too late, when patients have an extensive neurona...
Autores principales: | Mashal, Yara, Abdelhady, Hosam, Iyer, Arun K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313310/ https://www.ncbi.nlm.nih.gov/pubmed/35883556 http://dx.doi.org/10.3390/biom12071001 |
Ejemplares similares
-
Immunotherapy for the treatment of Alzheimer’s disease: amyloid-β or tau, which is the right target?
por: Castillo-Carranza, Diana L, et al.
Publicado: (2013) -
Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond
por: Song, Chenghuan, et al.
Publicado: (2022) -
Passive immunotherapies targeting Aβ and tau in Alzheimer's disease
por: Plotkin, Steven S., et al.
Publicado: (2020) -
The Dichotomy of Alzheimer’s Disease Pathology: Amyloid-β and Tau
por: Ashford, J. Wesson
Publicado: (2019) -
Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β
por: Vogt, Anne-Cathrine S., et al.
Publicado: (2023)